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Display of peptides or proteins in an ordered, repetitive array, such as on the surface of a virus-like particle, is known to induce an enhanced
immune response relative to vaccination with the “free” protein antigen. The coat protein of Tobacco mosaic virus (TMV) can accommodate short
peptide insertions into the primary sequence, but the display of larger protein moieties as genetic fusions to the capsid protein has not been
possible. We employed a randomized library approach to introduce a reactive lysine at the externally located amino terminus of the coat protein,
which facilitated biotinylation of the capsid. To characterize display of heterologous proteins on the virion surface, we bound a model antigen
(green fluorescent protein (GFP)–streptavidin (SA), expressed and purified from plants) to the biotinylated TMV particles, creating a GFP-SA
decorated virus particle. A GFP-SA tetramer loading of 26% was obtained, corresponding to approximately 2200 GFP moieties displayed per
intact virion. We evaluated the immunogenicity of GFP decorated virions in both mice and guinea pigs and found augmented humoral IgG titers in
both species, relative to unbound GFP-SA tetramer. Next, we fused an N-terminal fragment of the Canine oral papillomavirus L2 protein to
streptavidin. With TMV display, the L2 protein fragment was significantly more immunogenic than uncoupled antigen when tested in mice. By
demonstrating the presentation of whole proteins, this study expands the utility of TMV as a vaccine scaffold beyond that which is possible by
genetic manipulation.
© 2006 Elsevier Inc. All rights reserved.Keywords: Tobacco mosaic virus; Plant vaccine; Solubility; Streptavidin fusion; Biotin; Green fluorescent protein; Papillomavirus; AntibodiesIntroduction
Virus-like particles (VLPs) represented the first example of a
recombinantly expressed vaccine, with the licensure in the mid
1980s of two hepatitis B vaccines based on yeast-derived
hepatitis B surface antigen particles (HBsAg) (Hilleman, 1992).
Presently, subunit vaccines based on VLPs derived from the L1
capsid proteins of human papillomavirus (HPV) are in late-
stage clinical trials and have demonstrated remarkable efficacy
against their targeted HPV subtypes (Harper et al., 2004; Villa et⁎ Corresponding author. Fax: +1 707 446 3917.
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doi:10.1016/j.virol.2005.12.039al., 2005). The success of these antigens in inducing protective
immunity is due in large part to their highly ordered and
repetitive structure. The quasicrystalline nature of VLPs
facilitates pattern recognition by the specific and innate immune
systems and sustained antibody production as a consequence of
efficient activation of B cells through surface Ig cross-linking
(Bachmann et al., 1993, 1998). The immunostimulatory
properties of VLPs prompted their application as a platform
for the display of defined linear epitopes from diverse
pathogens, as well as self-antigens. However, for the most
part, published reports do not address the duration of the
protective immunity induced by these chimeric VLPs against
the target pathogen. A notable exception is a recombinant
chimeric HBsAg VLP, which displays a large fragment of the
circumsporozoite protein from the malaria parasite Plasmodium
falciparum. Several trials in humans have demonstrated that this
vaccine induced both strong antibody and T cell responses, with
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the protective immunity was relatively short lived, indicating
that further optimization in vaccine composition is required, to
elicit sufficient memory T helper (Th) cells to ensure an
anamnestic response (Bojang et al., 2001; Stoute et al., 1998).
Vaccines based on the display of only one or a few HLA-
restricted T cell epitopes on VLPs will limit the vaccine
applicability to only a subset of the patient population (Birkett et
al., 2002; Nardin et al., 2000). The field therefore needs new
methods to increase the number of pathogen specific CD4+-T
cell epitopes that may be displayed on VLPs, in order to remove
limitation to certain HLA genotypes and to bolster induction of
specific memory T cells. Also, as most pathogen-neutralizing
epitopes are conformational, restriction to the display of short,
linear peptide epitopes is a significant drawback of most VLP
epitope display platforms. Solution of these problems necessi-
tates an increase in the size of the protein fragment that is to be
displayed, which increases the potential for introducing protein
conformations that disrupt the capsid protein's primary
sequence, preventing particle formation (Karpenko et al.,
2000). Improved structural understanding of capsid formation
(Kratz et al., 1999) and genetic engineering approaches (Santa
Cruz et al., 1996) have permitted the display of GFP as a genetic
fusion to core antigen particles of hepatitis B (HBcAg) and to
potato virus X (PVX). A single chain functional antibody (scFv)
has also been displayed in the case of PVX (Smolenska et al.,
1998). However, GFP and scFvs are structurally compact, and
the ability to extend this approach to proteins with more
extended tertiary structures is unclear. Recently, the ectodomain
of the outer surface protein A from Borrelia burgdorferi was
fused to the HBcAg capsid (Nassal et al., 2005). This fusion was
particularly difficult to generate, and the final VLP preparation
was heterogeneous in nature, also containing incomplete parti-
cles and polymorphic multimeric structures. In addition, these
approaches may compromise the ability to recover purified
VLP, particularly in the case of filamentous capsids such as
PVX.
An alternative approach is to uncouple expression and
purification of the capsid scaffold and the heterologous protein
to be displayed, with subsequent conjugation of the desired
antigen to the VLP surface. Using this strategy, biotinylated
papillomavirus L1 VLPs were decorated with a streptavidin
fusion of the self-polypeptide TNF-α. This composition elicited
high-titer protective autoantibodies in a mouse model for type II
collagen-induced arthritis (Chackerian et al., 2001). Strategies
based on bifunctional cross-linkers with cowpea mosaic virus
(CPMV) (Chatterji et al., 2004) and HBcAg (Jegerlehner et al.,
2002) as scaffolds have also been described. Here, we report the
implementation of a platform for the display of whole foreign
proteins on the surface of TMV, in which the protein for
conjugation was also transiently expressed in planta via
recombinant TMV vectors, and subsequently purified. To obtain
a soluble scaffold for biotinylation that accumulated to high
levels required the evolution of a recombinant TMV with a
surface-exposed lysine. Streptavidin fusions of either GFP or an
N-terminal fragment (aa 61–171) of the Canine oral papilloma-
virus L2 protein (COPV L261–171) were conjugated to thisbiotinylated, lysine modified TMV capsid, and these complexes
were characterized. The papillomavirus minor capsid protein
(L2) is a promising vaccine candidate, as it induces antibodies
that can cross-neutralize different papillomavirus species, unlike
the major capsid protein (L1), which induces strictly type-
specific immunity. However, L2 is a poor immunogen and
requires potent adjuvants for induction of protective antibodies
(Pastrana et al., 2005; Roden et al., 2000). Since our primary
application of the TMV scaffold was to improve vaccine
immunogenicity, we compared the immune response obtained
with these VLP complexes to those generated by the free
streptavidin fusion proteins.
Results
Generation of a soluble and high yielding lysine modified coat
protein
Initially, to obtain a surface-exposed lysine, we engineered a
rTMV that expressed a coat protein (CP) with the amino acids
GKGAG fused to the N-terminus (LSB 2800). However, this
recombinant virus was suboptimal for our studies; the yield of
purified virion (Fig. 1A) was low (0.1–0.2 mg/g infected tissue).
This construct also aggregated upon storage at 4 °C (Fig. 1B). To
circumvent these problems, we used a library-based passage and
selection scheme to select for viruses displaying a surface-
exposed lysine that retained solubility at high protein concentra-
tions. A lysine was introduced at the N-terminus of the type U1
strain of TMV, with three randomized codons placed immedi-
ately upstream. Transcripts from approximately 3600 clones
were pooled and inoculated onto Nicotiana benthamiana plants
to generate a library of TMV CP mutants (library LSB 1295).
Isolation of virion from systemically infected tissue selected for
functional library members that possessed the desired purifica-
tion characteristics. The purified virus was stored for 2–5 days at
4 °C, at a concentration of 10 mg/ml or greater, to permit virion
with a propensity for aggregation to settle. We then used the
supernatant in three subsequent virus passages. A total of 74
isolates from this selected library were sequenced, and 11 unique
CP fusions were identified (Table 1). All isolates had at least one
acidic residue (glutamic acid or aspartic acid) one or two
residues N-terminal of the fixed lysine residue. Together, this
small collection of selected viruses suggests that one or more
surface-exposed acidic residues are needed to mitigate the
presence of the surface-exposed lysine. Eight of these individual
isolates were transcribed and inoculated onto plants to compare
yields with those obtained from virus LSB 2800 (Table 1).
Selected members of the LSB 1295 library represented a 10- to
70-fold yield improvement over virus LSB 2800, with
recoveries that exceeded 7 mg/g infected tissue noted for isolate
LSB 1295.10. On the basis of expression level and isolate
frequency, LSB 1295.4, with the amino acid sequence ADFK at
the CP N-terminus, was carried forward. We observed no
precipitation of this evolved and selected recombinant virus
(Fig. 1A), which represents a significant improvement in virus
physical properties relative to the original lysine-displaying
recombinant (LSB 2800) (Fig. 1B).
Table 1
Deduced amino acid sequence, frequency, and virion yield for a selection of
pLSB1295 library isolates
pLSB Sequence Frequency Yield mg/g
fresh weight
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in planta
Expression of the GFP-SA fusion in N. benthamiana plants
using a modified TMVexpression vector (Shivprasad et al., 1999)2800 M GKG SYS – 0.1–0.2
1295.1 M AEFK SYS 4 4.3
1295.2 M EVLK SYS 2 ND
1295.3 M AEVK SYS 13 1.3
1295.4 M ADFK SYS 27 5.2
1295.6 M DVEK SYS 2 2.0
1295.9 M EGAK SYS 7 0.9
1295.10 M EPMK SYS 1 7.3
1295.11 M EMGK SYS 4 4.3
1295.12 M DGAK SYS 1 2.7
1295.13 M EGLK SYS 13 ND
1295.14 M VEFK SYS 2 ND
ND, not determined.did not affect plant growth or biomass accumulation, with the
expected mosaic phenotype observed on systemically infected
tissue approximately 6 days post-inoculation. Near confluent
fluorescence of the systemically infected tissue occurred 8–9 days
following inoculation. The GFP-SA fusion was detectable in crude
plant extracts (Figs. 1C; GJ), migrating as a single band with an
apparent molecular weight of 40 kDa and of comparable intensity
to the TMV CP band, which migrated at 21 kDa. The yield of
purified fusion ranged from 60 to 120 mg/kg plant tissue
processed. By MALDI-TOF mass spectrometry, the observed
mass of the purified species was within 0.05% of 39,717.1 Da,
corresponding to full-length GFP-SA, with the methionine cleaved
and the N-terminal amine acetylated (data not shown). The
tetrameric form of core streptavidin is stable at 60 °C and below
(Bayer et al., 1990). To confirm tetramerization of GFP-SA,
samples incubated at 60 °C or 95 °C in SDS-PAGE loading buffer
were analyzed by gel electrophoresis (Fig. 1D). At 60 °C, the
prominent species migrated between 150 and 200 kDa, indicative
of tetramer formation, while at 95 °C, the 40-kDa fusion monomer
predominated, with a minor ∼12 kDa species also present.
Similarly, we expressed COPV L261–171-SA in planta using a
TMV vector and found the yield of purified fusion to beFig. 1. Purification and characterization of lysine modified rTMVs and the
fusion proteins GFP-SA and COPV L261–171-SA. LSB 2800, initial lysine
modified rTMV CP; LSB 1295.4, lysine modified rTMV CP selected on the
basis of expression level and solubility from a mitigating sequence library. (A)
SDS-PAGE analysis of crude homogenates from systemically infected N.
benthamiana plants (GJ) and the purified virions (F). GJ samples were diluted 5-
fold prior to loading. (B) Visual comparison of the rTMV solubility following
storage for 10 days at 4 °C and subsequently mixed to resuspend precipitate
(indicated by arrow). Protein concentrations were LSB 2800, 0.8 mg/ml; LSB
1295.4, 13 mg/ml. (C) Purification of GFP-SA by iminobiotin affinity
chromatography. S1, initial supernatant; S1 S, 25% ammonium sulfate
supernatant, S1 P, 25% ammonium sulfate pellet; L, affinity chromatography
load; FT, chromatography flow through; F1 and F2, elution fractions;•, GFP-
SA fusion. (D) Influence of temperature on the SDS-PAGE migration of LSB
1295.4 CP, GFP-SA and COPV L261–171-SA (L2-SA). Samples were incubated
in SDS-PAGE loading dye at 60 °C (60) and 95 °C (95) for 15 min prior to
analysis on a 10–20% Tris–glycine gel. MW, Mark 12 protein standard was
employed as a molecular weight marker on all gels.
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L261–171-SA fusion monomer migrated at 30 kDa by SDS-PAGE,
and tetramer formation was confirmed by a band shift to 116 kDa
(Fig. 1D). In addition, mass spectrometry confirmed N-terminal
methionine cleavage, and the principal species mass was within
0.05% of the expected value (24,894.8 Da; data not shown).
TMV biotinylation and complex formation with streptavidin
fusion proteins
In vitro biotinylation of the surface-exposed lysine of LSB
1295.4 was accomplished using the commercially available N-
hydroxysuccinimide (NHS) PEO4–biotin. LSB 1295.4 was
combined with the NHS-PEO4–biotin reagent at either a 24- or
240-fold molar excess relative to the viral CP and incubated for
up to 48 h at either room temperature or 4 °C. Although biotin
linker attachment to the 18 kDa CP represents only a 473-Da
increase in molecular weight, it resulted in a discernable shift by
gel electrophoresis (Fig. 2A) permitting the extent of CP
conjugation to be assessed. With a 24-fold excess of biotin
linker, approximately 20% of the virus surface was conjugated
(Fig. 2A), and biotinylation was confirmed by mass spectrom-
etry (Fig. 2B). To obtain fully biotinylated TMV, it was
necessary to incubate the LSB 1295.4 virus preparation at roomFig. 2. Biotinylation of the lysine modified LSB 1295.4 rTMV. (A) SDS-PAGE analys
a 24-fold (24) or 240-fold (240) molar excess of NHS-PEO4–biotin. The conjugations
24-h incubation; 48, 48-h incubation. MW 1, Magic Mark XP molecular weight mark
biotinylated LSB 1295.4 CP. A 24-fold molar excess of NHS-PEO4–biotin was emp
molar excess of NHS-PEO4–biotin and a 48-h incubation at 4 °C. (D) Protein blot wit
conjugate. (E) Protein blot with sample layout as in panel A, probed with GFP-SAtemperature in the presence of a 240-fold molar excess of the
linker (Figs. 2A and C). Under these conditions, we detected
two additional minor bands by gel electrophoresis. This
indicates conjugation of two or three biotins to a subset of the
TMV capsid proteins. We also observed these minor species
when we incubated type U1 CP with the biotin linker (Fig. 2A).
The identity of the minor conjugation species was confirmed by
mass spectrometry (data not shown). The biotinylated U1 CP
and the multiply conjugated LSB 1295.4 capsid protein were
detected, with comparable efficiency, by either a streptavidin
horseradish peroxidase conjugate or the TMV vector expressed
GFP-SA in Western blots (Figs. 2D and E).
To array the recombinant protein-SA tetramers on the surface
of the TMV, we used fully biotinylated virion preparations. The
GFP-SA was present at a 1.3-fold molar excess relative to
biotinylated CP, corresponding to a theoretical maximum
loading of 710 tetramers per virion rod. Following incubation,
the complex was isolated from unbound tetramer by sequential
precipitation using either ammonium sulfate or PEG. Control
reactions, employing non-biotinylated LSB 1295.4, demon-
strated the specificity of the tetramer association (Fig. 3A). The
complex recovered following PEG precipitation was examined
by electron microscopy and compared to the starting virus
scaffold, with and without biotinylation (Fig. 3B). The majorityis of conjugation reactions for wild-type TMV (U1) and LSB 1295.4 using either
were performed at either 4 °C or room temperature (RT). I, unconjugated CP; 24,
er; MW 2 Mark 12 molecular weight marker. (B) MALDI-TOF MS for partially
loyed with incubation at 4 °C for 24 h. (C) As for panel B, but with a 240-fold
h sample layout as in panel A, probed with a streptavidin horseradish peroxidase
and imaged under a UV-B source.
Fig. 3. Characterization of the rTMV/SA fusion complexes. (A) Visual comparison of GFP-SA association with LSB 1295.4 virion in the presence and absence of
surface displayed biotin. Following incubation, the TMV was precipitated by the addition of 25% w/v ammonium sulfate and centrifugation. 1295.4, non-biotinylated
rTMV; 1295.4 Bt, biotinylated rTMV. (B) Electron microscopy of rTMV/GFP-SA complex and the starting rTMV preparations. Top left, LSB 1295.4 virus; bottom
left, biotinylated LSB 1295.4 virus; right, biotinylated LSB 1295.4 virus complexed with GFP-SA. Scale bar represents 200 nm. (C) Comparison of virion surface for
uncoated rTMVand the rTMVassociated with either GFP-SA or COPV L261–171-SA. Top left, LSB 1295.4 virus; top right, biotinylated LSB 1295.4 virus (single 20s
disk is also visible); middle row, two images of rTMV/GFP-SA complex, with different levels of negative staining. Bottom row, two images of rTMV/COPV L261–171-
SA complex (a single 20 s disk encased by SA fusion is visible). Scale bar represents 100 nm. (D) SDS-PAGE analysis of the rTMV/GFP-SA complex and the separate
complex components following heating at either 60 °C or 95 °C. Legend; I, LSB 1295.4; Bt, biotinylated LSB 1295.4; I GFP SA, PEG precipitation of non-
biotinylated LSB 1295.4 combined with GFP-SA; Bt GFP SA, PEG precipitation of rTMV/GFP-SA complex; MW 1, Magic Mark XP molecular weight marker; MW
2, Mark 12 molecular weight marker. (E) Western blot probed with an anti-TMV polyclonal antibody. Lane order is identical to panel D. (F) Western blot probed with
an anti-GFP antibody. Lane order is identical to panel D.
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of the expected length (300 nm) with a diameter of 18 nm.
Complete biotinylation of the capsid proteins did not alter the
size distribution of the virus. However, in the case of
biotinylated TMV loaded with GFP-SA, we observed a notable
reduction in rod length: approximately 90% of rods were below
200 nm in length with 50–100 nm rods predominating. A
second electron dense layer, corresponding to the associated
GFP-SA, was clearly visible, increasing the diameter of the rods
to 29 nm (Fig. 3C). After extensive examination, we coulddetect no partially coated or uncoated rods, suggesting complete
coverage of the TMV capsid surface. When COPV L261–171-SA
was used in place of GFP-SA, a polydispersity in rod length was
also observed (data not shown), and all TMV capsids exhibited
a similar, additional electron dense layer (Fig. 3C).
The rTMV/GFP-SA complex was further characterized by
gel electrophoresis and Western blots (Figs. 3D–F). Incubation
at 60 °C, in the presence of SDS-PAGE loading buffer, resulted
in complete disassociation of the TMV virion; however, the
biotin/streptavidin linkage remained intact. The CP/tetramer
Fig. 4. Amino acid analysis of LSB 1295.4 rTMV (A) and the GFP-SA fusion
protein (B). Following acid hydrolysis of the purified proteins, the amino acids
were separated by ion exchange chromatography. Peaks corresponding to the
individual amino acids are identified using the one letter code. Nor, norleucine
internal standard; NH3, ammonia peak from amide deamination reactions which
occur during acid hydrolysis. Differences in the buffer/column system employed
for panels A and B resulted in the observed shift in the elution position for the
NH3 peak relative to the amino acid peaks. The TMVCP lacks histidine (H), and
this peak is therefore unique to the GFP-SA.
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alone. With incubation at 95 °C, the streptavidin/biotin linkage
was broken, and the GFP-SA and biotinylated CP migrated as
monomers (Fig. 3D). To confirm that the tetramer band shift
observed at 60 °C was the result of biotinylated CP association,
a Western blot was performed, with an anti-TMV polyclonal
antiserum used as the probe (Fig. 3E). The bands at N220 kDa,
which represent the complex (Bt GFP SA), were detected and
were also reactive when an anti-GFP (Fig. 3F) or anti-
streptavidin (data not shown) polyclonal antibody was used as
the probe. The control loading reactions, in which GFP-SAwas
combined with non-biotinylated LSB 1295.4 virus (I GFP SA),
were analyzed in parallel. These samples were also subjected to
sequential PEG precipitations. By gel electrophoresis, no GFP-
SA was detected in the PEG precipitated control samples (Fig.
3D). This was confirmed by Western blot (Fig. 3F), indicating
that the isolation procedure we employed for the rTMV/GFP-
SA complex effectively eliminated free SA fusion tetramers.
The rTMV/COPV L2 L261–171-SA complexes were analyzed in
parallel with similar results (data not shown).
Quantitative characterization of the rTMV/streptavidin fusion
complexes by amino acid analysis
The analysis described in Fig. 3 provides a qualitative
characterization of the complex generated but no information on
the level of virion decoration by the streptavidin fusion.
Initially, we used gel electrophoresis together with densitomet-
ric analysis of the Coomassie blue-stained bands to assess the
extent of TMV loading. However, the intensity of staining by
Coomassie brilliant blue is protein composition dependent
(Compton and Jones, 1985; de Moreno et al., 1986), preventing
quantitation of the CP and streptavidin fusion using a single
standard. Amino acid analysis was therefore investigated as an
alternative to quantitatively determine streptavidin fusion
loading. Since the full-length protein was determined to be
the predominant species for the LSB 1295.4 CP and both
streptavidin fusions, the amino acid composition of the complex
components can be related to the total picomoles of each residue
detected, by a series of linear algebraic equations. Five of these
equations are listed below (Eq. (1)) for the rTMV/GFP-SA
complex.
19 U1pmol þ 42 GFP-SApmol ¼ ASXpmol
12 U1pmol þ 26 GFP-SApmol ¼ LEUpmol
12 GFP-SApmol ¼ HISpmol
16 U1pmol þ 30 GFP-SApmol ¼ GLXpmol
11 U1pmol þ 11 GFP-SApmol ¼ ARGpmol
ð1Þ
In the present case, there are only two unknowns, the
picomoles of LSB 1295.4 CP and the picomoles of GFP-SA, so
at the minimum, two of the equations listed above are required
to define the complex. To determine the appropriate equations
to employ, three independent amino acid analyses were
performed for both the LSB 1295.4 virus and the GFP-SA, to
compare the experimental compositions obtained to the known
composition of each protein. Representative chromatograms forthe LSB 1295.4 CP and GFP-SA are shown in Fig. 4. A subset
of the amino acids for which the known and experimental
compositions agreed within ±3% were then used; the picomoles
of GFP-SAwas estimated from the picomoles of histidine in the
complex, since this amino acid was unique to the fusion (Fig.
4B), and this value was then employed in the equations for
arginine, leucine, and asparagine/aspartic acid, to obtain an
average for the picomoles of LSB 1295.4 CP present. The
composition of the complex used as immunogen in the animal
studies was determined to be an essentially equimolar ratio of
GFP-SA to LSB 1295.4 CP (1.05:1.0). This translated into 559
SA fusion tetramers, or 2200 GFP molecules, displayed per
intact virion. If we assume a 1:1 ratio between tetramer fusion
and biotinylated CP, a loading of 26% was achieved. When we
used this procedure for the rTMV/COPV L261–171-SA complex,
we found the level of streptavidin fusion association to be
comparable (data not shown). As an internal control, the total
picomoles of protein estimated by this composition-dependent
procedure was employed to back-calculate protein concentra-
tion and this value compared to the concentration obtained
using the data for all amino acids in a composition-independent
calculation, based solely on the molecular weight of the
individual amino acids. The two concentration values were
consistently within 10% of one another.
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antigen decorated virions
We compared the humoral immune response generated by
GFP or COPV L261–171 decorated virions with that obtained by
immunization with the respective streptavidin fusion alone, in
both mice and guinea pigs. For the mouse studies, antigen dose
was normalized to 1 μg and 10 μg of GFP or 2 μg and 20 μg
COPV L261–171, with the antigen administered in the absence of
adjuvant. A guinea pig study was also performed with GFP,
using a 10 μg dose, and for a subset of animals, the antigen was
co-administered with the adjuvant RIBI (Corixa, Hamilton,
MT). For the GFP-based studies, an additional control consisted
of GFP-SA combined with non-biotinylated LSB 1295.4 virus,
in proportions mirroring the complex composition (Table 2).
This group was included to differentiate between the effect of
physical association with the TMV capsid and the presence of
the capsid alone on the immune response.
After a single immunization, we observed augmented GFP
specific antibody titers in a subset of mice from the groups
administered rTMV/GFP-SA, relative to GFP-SA alone or the
streptavidin fusion mixed with the LSB 1295.4 virus. An
augmented response was observed at both the 1 μg and 10 μg
GFP doses (Fig. 5A). Following the second 1 μg GFPTable 2
Experimental set-up for the animal studies to evaluate the immunogenicity of the
rTMV/streptavidin antigen fusion complexes
Group Adjuvant Antigen
dose
(μg)
Antigen-SA
dose (μg)
rTMV
dose (μg)
M PBS No – – –
M GFP-SA alone
(GFP SA)
No 1 1.3 –
M GFP-SA +
unbiotinylated
rTMV (I GFP SA)
No 1 1.3 0.57
M GFP-SA/rTMV
complex (Bt GFP SA)
No 1 1.3 0.57
M GFP-SA alone No 10 13 –
M GFP-SA +
unbiotinylated rTMV
No 10 13 5.7
M GFP-SA/rTMV
complex
No 10 13 5.7
GP GFP-SA +
unbiotinylated rTMV
No 10 13 5.7
GP GFP-SA +
unbiotinylated rTMV
Yes 10 13 5.7
GP GFP-SA/rTMV
complex
No 10 13 5.7
GP GFP-SA/rTMV
complex
Yes 10 13 5.7
M COPV L261–171-SA
alone (L2 SA)
No 2 4.1 –
M COPV L261–171-SA/
rTMV complex
(Bt L2 SA)
No 2 4.1 2.6
M COPV L261–171-SA
alone (L2 SA)
No 20 41 –
M COPV L261–171-SA/rTMV
complex (Bt L2 SA)
No 20 41 26
Species; M, BALB/c mice; GP, guinea pigs.
Fig. 5. Comparative serological analysis of the immune response to the GFP-SA
alone or displayed on the surface of biotinylated LSB 1295.4 virion. (A) Serum
endpoint dilutions for the anti-GFP immune response observed in mice
following the first immunization. (B) Anti-GFP immune response observed in
mice following two immunizations. All immunizations were normalized to 1 μg
GFP per injection. (C) Serum endpoint dilutions for the anti-GFP immune
response observed in guinea pigs following two immunizations, normalized to
10 μg GFP per dose. RIBI was employed as an adjuvant. Legend for antigen
administered; PBS, PBS control; GFP SA, GFP-SA alone; I GFP SA, GFP-SA
mixed with non-biotinylated LSB 1295.4 virion; Bt GFP SA, rTMV/GFP-SA
complex.immunization, the mice administered the rTMV/GFP-SA (Bt
GFP SA) showed a robust immune response with endpoint titers
that were significantly higher (P value = 0.0001) than those
observed within the groups administered the free GFP-SA in the
presence or absence of non-biotinylated virus (Fig. 5B). At the
10 μg GFP dose, the differentiation between groups was not as
marked (data not shown). Conjugation of GFP to the TMV
capsid also elicited an improved immune response in guinea
pigs. After the second immunization, GFP-specific antibodies
were present in the sera of both animals administered the
482 M.L. Smith et al. / Virology 348 (2006) 475–488complex, while none were detectable in animals administered
the mixture of GFP-SA and non-biotinylated virus (Fig. 5C).
When the antigens were administered with RIBI adjuvant, the
differentiation between the groups was maintained with the
mean antibody titers elicited by the complex being 5- to 20-fold
higher than those observed with the free GFP-SA. With COPV
L261–171 as the target antigen, we observed a similar immune
response profile to that obtained with GFP. A clear augmen-
tation in antibody titer was evident following a single 20 μg
administration of the L2 protein fragment when the antigen was
biotin-TMV capsid-associated (Fig. 6A; Bt L2 SA). This initial
response was boosted significantly with re-administration of the
TMV complexed antigen (Fig. 6B). In contrast, the 20 μg dose
of the COPV L261–171 alone (L2 SA) produced only limited
boosting, and endpoint titers were on average 6-fold lower than
for the complex immunized animals (Bt L2 SA) (P
value b 0.0001). For the 2 μg COPV L261–171 dose, no group
differentiation was observed following one dose of antigen,
however, with TMV conjugation significant boosting occurred
with antigen re-administration.
Discussion
TMV has proven an effective carrier for the display of
foreign peptides, successfully eliciting a neutralizing immune
response against numerous target pathogens and in one reported
case, breaking B cell tolerance and inducing auto-reactive
antibodies (reviewed in Pogue et al. (2002)). However, the
display of peptide fragments exceeding 25–30 amino acids as
genetic fusions to the CP has been problematic and the amino
acid composition of the epitope, whatever its size, influences its
compatibility. To expand the utility of TMVas an antigen carrier
and overcome the antigen size limitations associated with
genetic modification, we investigated the use of a biotin-
decorated capsid for the presentation of antigen–streptavidin
fusions. Biotin was introduced by using NHS-PEO4–biotin, an
amine reactive conjugate of the vitamin. Although the TMV CP
contains two lysine residues (amino acids 54 and 69), predicted
to delineate the surface-exposed 60s loop, their reactivity with
the biotin conjugate was low (Figs. 2D and E), suggestingFig. 6. Comparative serological analysis of the immune response to the COPV L261–
Serum endpoint dilutions for the anti-COPV L2 immune response observed in mice f
in mice following two immunizations. Legend for antigen administered; L2 SA, COlimited solvent exposure. Since the terminal amino group was
also unreactive, owing to its acetylation in planta (Filner and
Marcus, 1974), the introduction of a surface-exposed amine was
required. Initially, a lysine flanked by two glycine residues was
fused to the N-terminus of CP, yielding the recombinant virus
LSB 2800. When purified, this fusion had a propensity to
aggregate, even at low protein concentrations (Fig. 1B). The
mechanism by which the addition of a basic residue results in
such poor solubility characteristics is not clear. We employed a
library-based approach to obtain a soluble TMV capsid with a
solvent-exposed lysine, by introducing three random amino
acids upstream of an N-terminal lysine. From the small number
of isolates sequenced (Table 1), a clear bias was evident for the
introduction of acidic residues, suggesting the need to mitigate
the presence of the added positive charge. Charge separation
was also preferred, with one or two predominantly aromatic or
aliphatic residues separating the acidic residue and the lysine for
the majority of the isolates, virus LSB 1295.6 being the
exception. Purified virus was obtained for 8 of the 11 isolates,
and no correlation was observed between the frequency of a
particular mitigating sequence and the rTMV yield. Virus titers
obtained in every case represented a notable improvement over
LSB 2800. Furthermore, the majority of the LSB 1295 virus
series remained soluble when stored at greater than 10 mg/ml,
as illustrated for LSB 1295.4 (Fig. 1B), the rTMV carried
forward in this study. Recently, Demir and Stowell (2002)
generated a lysine modified virion by introducing a single
amino acid mutation at the C-terminus of the native CP (denoted
T158K). To permit comparison with the mitigating sequence
capsids of the LSB 1295 library, we cloned, expressed and
purified the T158K recombinant (data not shown). Purification
was performed as outlined by Demir and Stowell, as well as by
the modified Gooding and Hebert (1967) procedure that we
employed for both LSB 2800 and the LSB 1295 virion series
(see Materials and Methods), and identity was confirmed by
mass spectrometry. The T158K mutant accumulation was 25- to
30-fold higher than for LSB 2800, with levels in the infected
tissue reaching 3 mg/g fresh weight and depending on the
purification route, yields of purified virus ranged from 0.9 to 1.5
mg/g fresh weight. To assess lysine accessibility, the T158K and171-SA alone or displayed on the surface of biotinylated LSB 1295.4 virion. (A)
ollowing the first immunization. (B) Anti-COPV L2 immune response observed
PV L261–171-SA alone; Bt L2 SA, rTMV/COPV L261–171-SA complex.
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PEO4–biotin. By protein gel electrophoresis, we observed a
similar level of biotin conjugation to both the T158K and LSB
1295.4 virions, suggesting the degree of solvent exposure for
the lysines in the two CP contexts was comparable. However, in
our hands, the T158K virus showed a marked propensity to
aggregate. When the T158K virus was centrifuged briefly, less
than 10% remained in the supernatant, irrespective of the
purification route employed. In contrast, when LSB 1295.4
virus was centrifuged in parallel, N98% remained soluble,
highlighting the benefits of the mitigating sequence library
approach (data not shown). Excessive aggregation of the TMV
scaffold will probably hinder processing of the assembled
complexes whether they be employed in vaccinology, other
medicinal applications or for the formation of nanomolecular
wires for electronic devices, as was proposed by others (Demir
and Stowell, 2002).
There are conflicting reports regarding the tolerance of TMV
for the addition of positively charged amino acids. The display
of two peptides tested by Bendahmane et al. (1999), containing
one or four basic residues, elicited necrotic lesions on the
inoculated leaves, a phenomenon that could be counteracted by
the introduction of acidic residues. Similarly for CPMV (Porta
et al., 2003) and zucchini yellow mosaic virus (Kimalov et al.,
2004), systemic infectivity was reduced with an increase in pI of
the displayed peptide. However, positively charged peptides
fused to TMV that show no deleterious host phenotypes and
which were easily purified have also been documented (Wu et
al., 2003). Our experience with positively charged epitopes
spans this spectrum, with the purified virus fusions also
showing a range of solubilities that can, in addition, be
influenced by whether the peptide is inserted at the N or C
terminus (LSBC, unpublished results). In sum, the data led us to
conclude that generalizations are of limited benefit and that
library based selection strategies similar to those we describe in
this paper may constitute a relatively rapid approach to
overcome the negative effects of any given epitope fused to
TMV CP or other viral capsid proteins. We have employed this
library-based approach for either lysine or cysteine display at
the C-terminus of the TMV U1 CP (inserted between amino
acids 155 and 156), as well as for the introduction of a surface-
exposed cysteine residue at either CP terminus. In all cases, the
solubility and accumulation of these evolved recombinant
virions were superior to the addition of either GKG or GCG,
and the virions were compatible with multiple homo- and
heterodimer linker chemistries (LSBC, unpublished results).
Modification of the native TMV CP was necessary because
the amino acid side chains commonly targeted for modification
were not represented on the virion surface. Recently, new linker
modalities have been designed, which permit chemical
modification of the native U1 CP and offer an alternative
strategy to the use of a recombinant TMV scaffold for antigen
display (Schlick et al., 2005). Biotin peptide mimics offer yet
another means for antigen display. The C-terminus of TMV has
been successfully modified to display the streptavidin-specific
heptapeptide sequence TLIAHPQ and tetramer association with
this recombinant virion was demonstrated (Negrouk et al.,2004). However, similar to 2-iminobiotin (Hofmann et al.,
1980), streptavidin affinity for this peptide mimic is orders of
magnitude lower than for biotin, with disassociation occurring
under acidic conditions. These characteristics will likely alter
the immunological characteristics of the complex and may be
attractive in certain cases. For example, rapid antigen unloading
following uptake into the acidic lysosomal compartment may
facilitate antigen cross-presentation, which is crucial in antiviral
immunity (Lizee et al., 2003). The breadth of choices in the
available capsid scaffolds introduces the possibility of tailoring
the vaccines characteristics to the generation of the most
appropriate immune response for the target disease.
Typically streptavidin fusions are expressed in bacterial
systems, and functional protein is recovered from the isolated
inclusion bodies following solubilization and refolding
(Kipriyanov et al., 1995; Sano and Cantor, 1991) with typical
yields of a few milligrams per 100 ml of culture (Sano and
Cantor, 2000). In the case of antigens whose neutralizing
epitopes are conformational in nature, there is always the
concern that the native tertiary structure may not be recovered.
The successful production of soluble and functional recombi-
nant streptavidin in Escherichia coli has been reported (Gallizia
et al., 1998); however, this approach does not yet appear to have
been extended to streptavidin fusions. For mammalian pathogen
antigens and self-antigens, eukaryotic expression systems may
offer improved epitope authenticity and circumvent the need for
protein refolding. There have only been a limited number of
reports describing the expression of streptavidin and avidin in
plants, and the production of fusions thereof has not been
described. By employing a transient TMV vector expression
system, plant development and foreign protein expression are
temporally segregated, facilitating the expression of streptavi-
din fusion proteins in the absence of toxic side effects which
have been observed when streptavidin is expressed in transgenic
plants (Murray et al., 2002). For the two TMV vector produced
streptavidin fusions described here (GFP-SA and COPV
L261–171-SA), this permitted the recovery of 60–120 mg of
functional tetramer/kg tissue, which compares favorably with
bacterial expression and obviates the need for a refolding step.
Rigorous qualification of recombinant vaccine composition
is critical if the products are to be developed commercially. We
showed that amino acid analysis of the two component
complexes permitted the quantitative determination of their
composition. This approach can be extended to any protein
complex, provided the individual components to be combined
are sufficiently characterized, for example by mass spectrom-
etry. Up to 18 linear algebraic equations can be derived relating
the picomoles of each protein to the picomoles of a given amino
acid, as outlined in Eq. (1). When only two components are
present, this introduces a high degree of redundancy, permitting
the independent determination of the moles of each protein
using pairs of equations and averaging of the results. This
procedure could in theory be extended to complexes consisting
of up to 18 unique components, although consideration of
amino acids sensitive to the protein hydrolysis procedure will
reduce the number of valid equations. For example, cysteine,
methionine, and tryptophan are destroyed during the 6 N HCl
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exercised in the equations chosen. As indicated in the Results,
we selected only amino acids that were accurately and
reproducibly quantified. For example, with the chromatography
and peak integration parameters employed, the isoleucine
composition was consistently underestimated by 16–18%.
The equation based on this amino acid was not employed as
the error would be propagated, yielding incorrect and/or
potentially meaningless solutions, e.g., negative picomoles of
a given protein component. In certain cases, it may be helpful to
tag the peptide or protein that is conjugated to TMV, to facilitate
quantitation of the conjugation efficiency; the TMV CP lacks
histidine (Fig. 4A), therefore, for this capsid a polyhistidine tag
would be appropriate, as this would provide a unique signature
in the chromatogram trace.
The size distribution of the biotinylated TMV capsids was
altered following decoration with the streptavidin fusions, with
the predominant rod length decreasing from 300 nm to 50–100
nm (Fig. 3B). The assembly of neutravidin onto the surface of
biotinylated TMV, already coated onto copper grids, has
previously been reported (Demir and Stowell, 2002). Although
these authors showed a similar level of decoration to that we
reported here, they made no comment regarding alterations to
the particle size distribution. In our case, we subjected the
decorated virions to a series of PEG precipitations to eliminate
unbound streptavidin fusion prior to analysis. It is possible that
fragmentation of the TMV conjugate rods occurred during this
additional processing, although no change in the particle size
distribution was observed for control samples (non-biotinylated
TMV mixed with streptavidin fusion) processed in parallel. An
alternative explanation is that the packing of the streptavidin
tetramers onto the capsid surface exceeded a critical limit,
resulting in rupture of the TMV rod. The SDS detergent, added
at 2% w/v with no heating, disrupts TMV virion yielding free
CP (data not shown), whereas biotinylated CP–streptavidin
association can occur in the presence of SDS and is stable up to
60 °C (Fig. 3D). This disparity in stability suggests that the
affinity of streptavidin for the biotinylated CP may be sufficient
for rod breakage when the streptavidin fusion is present in
excess of the packing limit, as was the case here. Since the
extent of capsid surface biotinylation can be easily controlled
(Fig. 2), this possibility can be addressed experimentally and if
necessary a level of biotinylation chosen that will give complete
surface coverage, while maintaining intact 300 nm rods. The
influence of the complex dimensions on the immune response
may also merit investigation. Early studies in rabbits adminis-
tered either 14C-labeled TMV virions or disassociated CP
demonstrated that the particulate nature of TMV resulted in
improved uptake by and activation of antigen presenting cells,
as the intact capsids were more effectively and rapidly
transported from the site of injection to proximal lymph
nodes, and then to the spleen (Loor, 1967). Further studies with
streptavidin fusion loaded rods, of different size distributions,
would permit the influence of rod length on the potency of the
immune response to be evaluated.
In the current study, we used GFP as a model antigen.
Clearly, physical association of the streptavidin fusion tetramersto TMV capsids augmented the immune response induced by
the TMV complexes, relative to free tetramer alone or tetramer
mixed with non-biotinylated rods (Fig. 5). After the second
immunization, total IgG titers were improved 4- to 20-fold in
both mice and guinea pigs, and with mice antibodies were
detectable after the first immunization for animals administered
the rTMV/GPF-SA complex. The robust immune responses to
relatively small amounts of antigen in the absence of adjuvant
led us to investigate whether the TMV–antigen coupling
approach could be used to improve the immune response to an
antigen that is notoriously poorly immunogenic—the minor
capsid protein of papillomaviruses. We found that the boosting
response obtained with COPV L261–171-SA was significantly
improved by TMV conjugation, which confirms the data we
obtained with GFP coupling to TMV, and reinforces our
conclusion that whole protein display on the TMV capsid is a
generally applicable approach for the augmentation of the
humoral immune response. Furthermore, we have observed that
complex formation with TMV is a requirement for the robust
induction of activated antigen-specific CD8+ T cells, which is
necessary for vaccines that require a cellular immune response
for efficacy (manuscript in preparation). These encouraging
results have provided a rationale for ongoing studies in our
laboratory, focusing on a series of antigen targets from human
immunodeficiency virus, human papillomavirus, and their
respective preclinical models. Facile systems for the display
of heterologous proteins on the surface of icosahedral capsids
and their therapeutic potential have been reported (Chackerian
et al., 2001; Jegerlehner et al., 2002). The current work extends
capsid display for therapeutic applications to another geometry,
that of rod-shaped capsids, thereby increasing the density with
which whole antigens may be displayed compared to competing
VLP systems. On a T = 3 particle such as hepatitis B core
antigen VLP, 180 tetramers can be theoretically accommodated,
while the capacity of a T = 7 particle such as papillomavirus is
420. The 26% loading obtained in the present study corresponds
to 550 tetramers per intact 300 nm long virion, and for cases
where the antigen fusion partner to streptavidin is smaller, a
further increase in the TMV packing density is theoretically
possible, while for the icosahedral platforms, it will remain
constant.
Materials and methods
Generation of soluble tobacco mosaic virus displaying a
surface-exposed lysine
The amino terminus of the TMV CP resides on the exterior
of TMV particles, allowing amino acids fused to the N-terminus
of the TMV CP to be displayed on the virion surface. Using
standard molecular techniques, codons for the amino acid
sequence glycine–lysine–glycine–alanine–glycine (GKGAG),
were fused to the 5′ end of the TMV CP ORF in a plasmid
containing the full-length cDNA clone of TMV RNA, under the
control of the T7 RNA polymerase promoter. The resulting
plasmid was named pLSB 2800. T7 transcripts of pLSB 2800
were inoculated onto N. benthamiana plants to generate LSB
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of the plasmid-based cDNA clones. This nomenclature is
followed throughout this manuscript). LSB 2800 was purified
from systemically infected N. benthamiana plants, by a
modification of the procedure of Gooding and Hebert (1967).
Briefly, the tissue was homogenized in 0.86 MNaCl, 0.04% w/v
sodium metabisulfite (0.5 g of tissue/ml of buffer), adjusted to
pH 5.0, heated to 47 °C for 5 min, chilled and centrifuged at
6000 × g for 5 min. The clarified supernatant was subjected to
two sequential PEG precipitations to recover the virus. This
concentrated virus was extracted with 25% chloroform v/v, to
remove host protein impurities and pigments that remained
associated with the virus.
Due to LSB 2800 aggregation with storage, a library-based
strategy was undertaken, to construct a recombinant TMV CP
having both a surface-exposed lysine residue and high solubility.
Using a PCR-based approach, three randomized codons and a
lysine codon were fused to the 5′ end of the U1 CP ORF. The
TMV CP gene and 3′ UTR were amplified from a full-length
cDNA clone of the U1 strain of TMV (p801) using oligonucleo-
tides JAL 613 (CGAACCATGGNNNNKNNKAAATCTTA-
CAGTATCACTACTCCATCTCA) as a forward primer and JAL
590 (GCCAACACATCCGGGTACCTGGGCCCCTA) as a re-
verse primer. The resulting PCR product of about 800 bp was
digested with NcoI (underlined in JAL 613 sequence) and KpnI
(underlined in JAL 590 sequence) and ligated into NcoI, KpnI
digested pJL 150/254 to produce the CP library, pLSB 1295. The
pLSB 1295 library was transformed into DH5α E. coli and plated.
DNA was prepared from a pool of about 3600 colonies of this
library, linearized with KpnI and transcribed with T7 RNA
polymerase using the T7 mMessage mMachine kit (Ambion,
Austin, TX), according to manufacturers' instructions. Transcript
was inoculated onto 12 N. benthamiana plants at a concentration
of approximately 100 infectious units per plant.
Approximately 8–10 days post-inoculation, one systemically
infected leaf from each N. benthamiana plant was harvested and
pooled. TMV particles were purified from the pooled infected
leaves as described above, by extracting in a buffer lacking NaCl
and omitting the final chloroform treatment. The purified virus
was passaged for three additional cycles, with the virus purified
between each cycle. After the final virus purification, RNAwas
isolated using the Qiagen RNAeasy kit (Valencia, CA),
according to the manufacturers' instructions. The CP gene was
amplified from the purified viral RNA using the Promega
ImPromII RT-PCR kit (Madison, WI) and the oligonucleotide
JAL 619 (GCCTTGGTACCTGGGCCCCTACCGGGGG-
TAACGG). The CP gene region and 3′ UTR were subsequently
amplified from the RT reaction product using oligonucleotides
JAL 618 (CGATGATGATTCGGAGGCTACTG) and JAL 619
as forward and reverse primers, respectively. The resulting PCR
product was digested with NcoI and KpnI and ligated into NcoI-
KpnI digested pJL 150/254. This ligation reaction was trans-
formed into DH5α E. coli, and DNA samples from individual
colonies were sequenced to determine the coding sequence at the
5′ end of the CP gene for isolates from the selected library.
To obtain virus samples of recombinant clones from the
selected library, transcript was generated, inoculated onto N.benthamiana plants and TMV particles purified from system-
ically infected tissue as described earlier. Individual virus
samples were analyzed by protein gel electrophoresis, and mass
spectrometry was performed to confirm the identity of the
additional amino acids on the CP N-terminus.
Cloning, expression, and purification of the streptavidin
fusions
Purified Streptomyces avidinii genomic DNA was obtained
from ATCC (Manassas, VA), and the streptavidin core (SA)
coding sequence (372 bp covering amino acids 40–163 of the
Swissprot accession number P22629) was amplified by PCR.
The SA coding sequence was ligated to the SacI site in the GFP
insert in the TMV expression vector, p30B GFPc3 (Shivprasad
et al., 1999), using standard cloning techniques, resulting in a
fusion of GFP to the N-terminus of the streptavidin core. This
plasmid, pLSB 1290, was modified further to remove the GFP
and to introduce the NgoMIVand AvrII restriction sites at the N-
terminus of the SA core to facilitate additional cloning (plasmid
pLSB1821). A DNA fragment, corresponding to amino acids
61–171 of the L2 protein of COPV (Genbank accession number
NP056818), COPV L261–171, was synthesized by Geneart
(Regensburg, Germany) using the preferred codon usage of
tobacco. Following NgoMIV and AvrII digestion, the fragment
was cloned into pLSB1821 to generate plasmid pLSB1825.
Infectious transcripts, prepared from pLSB1290 or pLSB1825,
were inoculated onto N. benthamiana plants.
To isolate the GFP-SA fusion, infected plant tissue was
homogenized in three volumes of extraction buffer (100 mM
phosphate pH 7.2, 0.01% Na-metabisulfite, 1 μl BME per ml)
and filtered through cheesecloth. Following heat treatment at
52–55 °C for 7 min, the homogenate was centrifuged at
12,000 × g for 10 min and an initial 25% ammonium sulfate cut
performed on the clarified supernatant. The GFP-SA containing
protein fraction was precipitated with 50% ammonium sulfate,
resuspended to 1/5th the original volume, and dialyzed against
1× phosphate-buffered saline (PBS), adjusted to pH 9.3. For
COPV L261–171-SA, 25 mM Tris-maleic acid, pH 7.5, 2 mM
EDTAwas employed as the extraction buffer, the heat treatment
omitted and 0.4% w/v polyethyleneimine added to facilitate
clarification. A single 30% ammonium sulfate cut was
performed to concentrate COPV L261–171-SA.
Affinity chromatography was performed using an AKTA
purifier 10 system (Amersham Biosciences, Piscataway, NJ).
The clarified plant extract was adjusted to pH 11 and loaded
onto an immobilized iminobiotin resin (Pierce, Rockford, IL)
using 1 ml resin per 20 g tissue extracted. The captured
streptavidin fusion was eluted using 0.1 M acetic acid, pH 4.0
and the peak fractions dialyzed against phosphate buffer prior to
storage.
Biotinylation of the LSB 1295.4 rTMV surface-exposed lysine
From the library passage experiment, multiple unique
recombinant viruses were obtained (Table 1) which remained
soluble post-purification at concentrations of 10 mg/ml or
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terminal amino acids ADFK was selected for in vitro
biotinylation reactions. Biotin was covalently conjugated to
the surface-exposed lysine using EZ-Link NHS-PEO4–biotin
(Pierce, Rockford, IL). Lyophilized NHS-PEO4–biotin was
dissolved in phosphate buffer containing the rTMV at a
concentration of 0.8 mg/ml, with the biotin analog typically
present at a 24-fold or 240-fold molar excess. The conjugation
reactions were incubated with mixing at either 4 °C or room
temperature, for up to 60 h, as described in the Results.
Unreacted NHS-PEO4–biotin was removed by PEG precipita-
tion of the biotinylated rTMV (4% w/v PEG, 4% w/v NaCl),
and the biotinylated virus was resuspended in 1× PBS.
Analytical procedures, immunoassays, and electron
microscopy
Polyacrylamide gel electrophoresis (PAGE) of proteins in the
presence of sodium dodecyl sulfate (SDS) (Laemmli, 1970) was
performed on 10–20% Tris glycine gels (BioRad, Hercules CA,
or Invitrogen, Carlsbad, CA), following the manufacturers'
instructions. The Mark 12 or Magic Mark XP proteins standards
(both Invitrogen) were employed as molecular weight refer-
ences. Western blots (Towbin et al., 1979), employing 0.2 μm
polyvinylidene fluoride membrane (BioRad) were probed with
either rabbit anti-TMV polyclonal, PVAS-135D (ATCC) or a
rabbit anti-GFP polyclonal (Polysciences, Warrington, PA). In
both cases, the secondary antibody was a goat anti-rabbit
horseradish peroxidase (HRP) conjugate (BioRad). To evaluate
rTMV biotinylation, blots were probed with either streptavidin
HRP (Pharmingen, San Diego, CA) or the GFP-SA fusion. HRP
detection was with the ECL+ chemiluminescent kit (Amer-
sham) with Hyperfilm ECL (Amersham) employed for image
capture, as per the manufacturers' instructions.
Amino acid analysis (AAA) was performed by the Molecular
Structure Facility at the University of California, Davis. Protein
quantitation was also performed using the bicinchoninic acid
(BCA) assay (Pierce) in a microtiter plate format following the
manufacturers' instructions. Wild-type TMV, type U1, quanti-
fied by AAA was employed as a standard. Protein mass
determination was performed by matrix-assisted laser desorp-
tion ionization time-of-flight mass spectrometry (MALDI-TOF
MS) using a Voyager-DE STR Biospectrometry Workstation
(Applied Biosystems, Foster City, CA). The mass spectrometer
was operated in linear and positive mode using delayed
extraction at an accelerating voltage of 25 kV and 128 laser
shots per spectrum. A single point mass calibration was
performed using horse heart apomyoglobin (Sigma, St. Louis,
MO). All MALDI-TOF sample spotting in sinipinic acid was
performed using a dried-droplet method (Karas and Hillen-
kamp, 1988). All raw spectral data were processed using
Applied Biosystems Data Explorer 4.0.0.0. Protein identifica-
tion was determined using General Protein/Mass Analysis for
Windows (GPMAW), version 5.0 (Lighthouse Data, Denmark)
software.
For electron microscopy, grids (400 Mesh copper, carbon
coated; Ted Pella, Redding, CA) were floated on drops of 1×PBS, containing rTMV or the rTMV/streptavidin fusion
complex, diluted to a concentration of 100–200 μg/ml (relative
to the rTMV alone). Following a 15-min contact time, excess
liquid was removed, the grids negatively stained with 1%
phosphotungstic acid (PTA) and permitted to air dry. Bacitracin
at 25 μg/ml was employed during both the sample coating of the
grid and negative staining (Gregory and Pirie, 1973). All
samples were examined on a Philips CM120 microscope,
coupled to a Gatan MegaScan 795 digital camera.
Manufacture of the rTMV/streptavidin fusion complexes
Affinity purified GFP-SA was combined with biotinylated
rTMV, to obtain a final GFP-SA to rTMV CP mass ratio of 3:1.
For COPV L261–171-SA, the mass ratio of streptavidin fusion to
rTMV CP was 1.4:1. The mixture was incubated for 4 h or
overnight at room temperature, with gentle agitation, to allow
the streptavidin fusion to bind to the biotinylated virion. For the
rTMV/GFP-SA mixtures, unbound GFP-SA was removed by
precipitation of TMV particles with 4% PEG (MW 6000), 4%
NaCl and centrifugation for 15 min at 10,000×g. The PEG
precipitation steps were repeated twice, and a control incubation
employing non-biotinylated rTMV was processed in parallel.
Siliconized centrifuge tubes and pipettes were employed during
the manufacturing.
Immunogenicity testing in mice and guinea pigs and
serological analysis
The immunogenicity of the rTMV/GFP-SA complexes was
evaluated in both mice and guinea pigs. The murine studies
were performed using 6- to 8-week-old female BALB/c mice
(Harlan Sprague–Dawley, Indianapolis, IN). Mice received two
immunizations, administered subcutaneously at 2-week inter-
vals in the absence of adjuvant. Tail bleeds were taken 9 days
after each injection. All dosing was normalized to the mass of
GFP administered, with animals receiving either 1 μg or 10 μg
GFP. Groups of five mice were employed, and the high and low
responders from each group were omitted in the analysis. For
the guinea pig study, 20-week-old animals (Harlan Sprague–
Dawley) (2 per group) received a total of two 10 μg GFP
immunizations delivered at four sites along the back. For half
the groups, the antigens were combined with the adjuvant RIBI
(Corixa, Hamilton, MT), as per the manufacturers' instructions.
Antigen was administered at 4-week intervals, with bleeds taken
2 weeks after each injection by intravenous puncture of the
cranial vena cava. The murine study to test the COPV L261–171-
SA was similar in design to that described above, except that
groups consisted of six animals, and the normalized COPV
L261–171 doses were 2 μg or 20 μg. Table 2 summarizes the
antigen groups evaluated for both the murine (M) and guinea
pig (GP) studies.
Antibody response to antigen was determined by enzyme-
linked immunosorbent assay (ELISA). 96-well microtiter plates
(MaxiSorp; Nalge Nunc, Rochester, NY) were coated with
either GFP (TMV vector expressed and purified to N90%) or a
bacterially expressed COPV L2 fragment (amino acids 38–160)
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bovine serum albumin, serial dilutions of the sera were added.
Following a 1-h incubation, the plates were washed and
incubated for an additional hour with the appropriate HRP-
conjugated secondary antibodies; goat anti-mouse IgG (South-
ern Biotechnology Associates, Birmingham, AL) or goat anti-
guinea pig IgG (Bethyl Laboratories, Montgomery, Texas).
Plates were developed using a tetramethyl benzidine substrate
solution (Turbo TMB ELISA; Pierce), and the reactions stopped
by the addition of 1 N sulfuric acid. Plate absorbance was read
at 450 nm in a 96-well plate spectrophotometer (Molecular
Devices, Sunnyvale, CA). The serum endpoint dilution
corresponded to an absorbance reading of twice background.
Data and statistical analysis (unpaired t tests) was performed
using GraphPad (version 4.0) (San Diego, CA).
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